These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25986722)

  • 1. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
    Nastoupil LJ; Neelapu SS
    Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
    Cheah CY; Fowler NH; Neelapu SS
    Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Bounaix L; Bendouda M; Bay JO; Lemal R
    Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
    Bröckelmann PJ; Engert A
    Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
    Fessas P; Lee H; Ikemizu S; Janowitz T
    Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.